Objective Human donor pancreases can be processed to islet cell grafts but less than 50 percent of isolates reach criteria for clinical transplantation. Donor, procurement and processing conditions are considered to influence this utility rate (1). The Brussels Beta Cell Bank receives organs procured from donors after brain death (DBD) or after circulatory death (DCD) from the Eurotransplant network. The subgroup of DCD involving euthanasia (DCD-V) has been associated with excellent outcome of solid organ transplants (2). The present study evaluates its outcome in the preparation of islet cell grafts. Methods A retrospective analysis was performed using the database of our Beta Cell Bank containing donor and procurement characteristics as well as quality control data of the isolates, such as yield in dithizon (DTZ, marker for endocrine cells) positive cell volume and utility for clinical transplantation. Results Over the last four years, 292 pancreases were processed, 7 of which from DCD-V. Higher islet cell yields were obtained from DCD-V compared to DCD-III or DBD (490 µl DTZ versus 232 µl DTZ and 279 µl DTZ respectively, p < 0.05). This led to higher use for clinical transplantation (100% vs 39% and 44%, p < 0.01). These better outcome parameters can at least in part be attributed to a lower glycemia of the donor prior to organ procurement (p < 0.001), to a shorter surgical extraction time (p < 0.05), and to a shorter cold ischemia time (p < 0.001). Conclusions The markedly higher clinical utility of islet cell isolates prepared from post-euthanasia-donor pancreases underlines the critical importance of donor and procurement conditions for this type of graft.
Original languageEnglish
Publication statusPublished - 3 May 2018
EventBelgian Surgical Week: The Expanding Universe of Surgical Technology - Thermae Palace, Oostende, Belgium
Duration: 3 May 20185 May 2018


ConferenceBelgian Surgical Week

ID: 37700362